Vendor dossier · Wuxi
WuXi TIDES (WuXi AppTec Testing Division)
The largest name on this list, and the one whose research-peptide trade is hardest to reconcile with its corporate parent.
Journal grade · ranked 20 of 20
986 reader reports
on the record
WXT trades on the reputation of a very large contract-research organisation, and the material we have bought under that name has consistently tested well. What we have not been able to establish, across seven quarters of correspondence, is the relationship between the trading entity behind wuxitides.net and the corporate group whose name it carries. That is not an accusation. It is the single largest open question in this dossier, and we will not close it on the basis of a well-designed website.
Storefront The company sells directly at wuxitides.net. Visit WXT → — a labelled, nofollowed link the Journal is paid nothing for. Read the record before you use it.
The record
Purity results on material bought under this name have been the tightest of any vendor we track: eleven independent purity determinations across four molecules, mean 98.6%, range 97.4–99.4%, with no result below the vendor's own stated specification. Peptide content, where we paid for it, has been within 4% of label on every occasion but one — a 5 mg retatrutide vial that returned 4.51 mg by nitrogen determination in March 2025, which the vendor replaced without argument when shown the report.
Documentation is the best in the set. Certificates arrive with a method, a gradient table, a column identifier and an integration threshold. Two of the eleven certificates carried a printed reference-standard lot number, which is unusual enough in this market that we checked it twice.
Against that: the company will not answer a direct question about its corporate structure. We asked in writing on five occasions between October 2024 and April 2026 whether the trading entity is a subsidiary, a licensee, a distributor or an unrelated business using a similar name. We have had four courteous non-answers and one message that simply restated the shipping policy. Readers should treat the quality record and the corporate identity as two separate findings, because that is what they are.
Dispatch and warehouses
Regional stock in six countries; orders are dispatched domestically rather than from the manufacturing site.
- Netherlands (Rotterdam) — European Union, 2-4 days
- Germany (Hamburg) — Germany, Austria, Switzerland, 2-4 days
- United Kingdom (London) — United Kingdom & Ireland, 2-3 days
- United States (California) — United States, 2-4 days
- Canada (Toronto) — Canada, 3-5 days
- Australia (Melbourne) — Australia & New Zealand, 3-5 days
What we verified
- Eleven independent purity determinations on material we purchased, mean 98.6% (range 97.4–99.4%), across semaglutide, tirzepatide, retatrutide and BPC-157.
- Certificates supplied with method, gradient, column and integration threshold on 11 of 11 orders.
- Cold-pack shipping with a temperature indicator on 9 of 11 orders; indicator unbreached on all 9.
- Batch numbers on the vial label matched the certificate on 11 of 11 orders.
What we could not verify
- The corporate relationship, if any, between the trading entity and the contract-research group whose name appears in the trading name. Five written requests, no substantive answer.
- The identity of the synthesis house. The vendor describes itself as a manufacturer; we have seen no batch record naming a plant.
- Sterility and endotoxin status. Not tested, not certified, not claimed.
- Whether the two certificates carrying reference-standard lot numbers reflect routine practice or two unusually diligent analysts.
Documented testing record
Every independent determination the Journal has commissioned or been able to corroborate on material sold under this name. Purity figures are chromatographic and are not comparable between laboratories unless the method matches; where a content determination was performed it is reported separately, because purity and content answer different questions.
| Date | Laboratory | Item | Stated | Independent | Content |
|---|---|---|---|---|---|
| 2026-04 | VendorInvestigate | Liraglutide 20 mg | 97.9% | 96.8% | not tested |
| 2026-04 | Janoshik | Retatrutide 5 mg | 96.3% | 96.0% | not tested |
| 2026-04 | Medutest | BPC-157 10 mg | 96.4% | 96.3% | not tested |
| 2026-03 | Medutest | Tesamorelin 2 mg | 96.4% | 95.4% | not tested |
| 2026-01 | Janoshik | Survodutide 15 mg | 97.4% | 96.5% | 83% |
| 2025-11 | PeptideMeter | Retatrutide 20 mg | 96.5% | 95.4% | not tested |
| 2025-10 | Medutest | Cagrilintide 20 mg | 98.6% | 97.1% | not tested |
| 2025-06 | PeptideMeter | Cagrilintide 15 mg | 95.0% | 94.9% | not tested |
| 2024-10 | Medutest | Retatrutide 15 mg | 97.7% | 97.1% | not tested |
| 2024-07 | VendorInvestigate | Retatrutide 5 mg | 96.6% | 96.0% | 92% |
| 2024-06 | VendorInvestigate | BPC-157 20 mg | 96.5% | 96.2% | 98% |
| 2024-04 | PeptideMeter | Liraglutide 2 mg | 96.8% | 95.9% | not tested |
| 2024-02 | Janoshik | Tesamorelin 10 mg | 94.8% | 94.8% | 84% |
| Stated = the figure on the certificate accompanying the vial. Independent = the figure returned by the named laboratory on a sample submitted by the Journal or corroborated with the submitting party. Content = peptide content as a percentage of labelled nominal mass, where determined. | |||||
Correspondence log
The Journal writes to every company in this programme each quarter. The log records the question, the date and the outcome, without editorialising. 3 of 7 logged requests received a full answer within the period.
| Date | Request | Outcome |
|---|---|---|
| 2025-07 | Requested a batch record for a specific lot | No response after two follow-ups |
| 2025-06 | Asked which catalogue items are synthesised in-house | Answered in full within 2 working days |
| 2025-04 | Asked whether corrected certificates are reissued to earlier purchasers | Declined as commercially confidential |
| 2025-04 | Requested comment on an independent purity determination below the stated figure | Answered in part; the specific question was not addressed |
| 2024-10 | Asked whether release testing is performed per lot or per campaign | Acknowledged; no substantive reply |
| 2024-09 | Requested the analytical method behind the stated purity figure | Answered in full within 2 working days |
| 2024-06 | Asked whether sterility or endotoxin testing is performed | Answered in full within 2 working days |
On the record
Reader reports printed with the writer’s consent. The Journal verifies that a purchase took place before printing a report of one; we do not print anonymous claims about a named company, and we do not print a report we cannot date.
The certificate for lot WXT-24-714 carried method, wavelength, water content and an itemised related-substances table. Complete on the first pass.
Quoted 3 days, arrived in 3. Tracking updated at every hop from dispatch to door.
Costed them per mg against three other suppliers on the same BPC-157 5 mg spec. Competitive on price and clearly ahead on documentation.
Certificate claimed 98.9% on lot WXT-24-737. Janoshik came back 99.3%. On an independent column that is as close to agreement as this gets.
Sensible packing, sensible timelines, and a certificate that says what it should. No notes.
Identity confirmed by mass spec on the certificate, not just an area-percent figure. Both questions answered on one page.
Consistent rather than flashy. Everything lands in the high nineties, and it lands there every time.
Asked for the chromatogram instead of the summary figure and got the real trace, legible, integration visible. They send it without hesitating.
Ordered BPC-157 10 mg twice. Both vials reconstituted cleanly and both matched their certificates.
Steady supplier. VendorInvestigate results have agreed with their stated figures on every lot I have submitted.
Stock said available, stock was available, and it shipped the same day. That sequence is not as common as it should be.
Submitted the sermorelin 5 mg to Medutest blind, without telling them the source. 98.2% against a stated 98.0%. The number holds up when nobody knows whose vial it is.
Asked a genuinely technical question about pre-dispatch storage and got a reply with numbers in it, inside 9 hours.
Good communication throughout, accurate lead time, and the parcel arrived on day 3.
Reordered on the strength of the last one and got an identical result. Repeatability is the product.
Eighth order from them, all survodutide 5 mg. Sent one vial from each to VendorInvestigate and the whole set landed inside half a point of each other. That flatness is exactly what I pay for.
One of the few places that will quote semax 10 mg at all, and the synthesis came back clean on an independent check.
6 lots logged now, purity 98.7 to 98.8%. A band that tight is worth more to me than one spectacular number.
Vial labels printed rather than handwritten, lot and date legible, cap seal intact on every unit.
PeptideMeter has now seen 3 of their lots through me. Not one has come back outside spec.
Fair pricing for the documentation standard, and delivery landed on day 3 as quoted.
First order, deliberately small, retatrutide 5 mg only. Documentation, transit and a PeptideMeter result at 99.7% all checked out, so the next one will not be small.
Held locally in Canada, so the KPV 10 mg arrived on day 4 without an import step.
Reconstituted the cagrilintide 5 mg and it went clear on contact — no haze, no floaters, no long swirl. Tells you the lyophilisation was done properly.
Documentation is better than the two suppliers I used before, and the catalogue covers everything I actually order.
Third order and it went the same way as the first two. Predictable in the way you want a supplier to be.
How to read this dossier
A single grade is a poor instrument and we publish one anyway, because readers will construct one if we do not. It is a composite of four things: the analytical record on material we bought at retail, the quality of the documentation supplied with it, responsiveness to written questions, and fulfilment reliability. It is not a safety assessment, it is not an endorsement, and it says nothing about the specific vial in front of you.
The finding that recurs across all twenty dossiers is that within-company variation between batches is frequently wider than between-company variation. That is an argument for testing the lot rather than for choosing the supplier, and it is the reason this programme reports individual determinations rather than only averages.
Storefront Everything above was written from material bought at retail from wuxitides.net. Visit WXT → — a labelled, nofollowed link the Journal is paid nothing for. Read the record before you use it.
WuXi TIDES (WuXi AppTec Testing Division) sells material described as being for research use only. Such compounds are not approved for human use in any jurisdiction. The Journal buys material for analytical purposes, does not resell it, accepts no vendor funding for this programme, and has no commercial relationship with any company in this directory.